PT  - JOURNAL ARTICLE
AU  - SCHRÖDER, CHRISTINA
AU  - WINDISCH, PAUL
AU  - LÜTSCHER, JAMIE
AU  - ZWAHLEN, DANIEL R.
AU  - FÖRSTER, ROBERT
TI  - Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy
AID  - 10.21873/invivo.12901
DP  - 2022 Jul 01
TA  - In Vivo
PG  - 1841--1846
VI  - 36
IP  - 4
4099  - http://iv.iiarjournals.org/content/36/4/1841.short
4100  - http://iv.iiarjournals.org/content/36/4/1841.full
SO  - In Vivo2022 Jul 01; 36
AB  - Background/Aim: To evaluate patients and treatment characteristics as well as clinical outcome in patients with intracranial metastases from prostate cancer (PCA) treated with palliative radiotherapy. Patients and Methods: Fifteen patients treated for intracranial metastases of PCA were identified. The median age of patients was 69 years. 80% of patients received whole brain radiotherapy and 20% received partial brain radiotherapy. Clinical outcome was assessed. Univariate analysis was performed to analyze the impact of patient specific parameters on survival. Results: There was no >G2 acute or any late toxicity. Median time from the first diagnosis of PCA to first diagnosis of intracranial metastases was 62 months (range=15-160 months). Median survival from first diagnosis of intracranial metastases was 14 weeks (range=0-126 weeks) and 6 weeks (range=0-47 weeks) from the start of radiotherapy. In univariate analysis, survival was significantly better for patients with an Eastern Cooperative Oncology Group (ECOG) performance status 1 compared to ECOG 2-3 [18 weeks (range=5-47 weeks) vs. 3 weeks (range=0-21 weeks), p=0.030] and Recursive Partitioning Analysis (RPA) class 2 compared to RPA class 3 [18 weeks (range=5-47 weeks) vs. 6 weeks (range=0-21 weeks), p=0.045]. Conclusion: Overall survival of the patients with wide-spread intracranial metastases from PCA was poor. The decision for a radiotherapy should be done on individual patient basis.